Bicycle Therapeutics Ltd
$ 3.97
0.00%
06 Aug - close price
- Market Cap 277,872,000 USD
- Current Price $ 3.97
- High / Low $ 4.03 / 3.93
- Stock P/E N/A
- Book Value 7.95
- EPS -2.72
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.34 %
- 52 Week High 9.16
- 52 Week Low 3.75
About
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Analyst Target Price
$9.86
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-03-17 | 2025-10-30 | 2025-08-08 | 2025-05-01 | 2025-02-25 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-20 | 2023-11-02 |
| Reported EPS | -0.72 | -0.87 | -0.29 | -0.85 | -1.14 | -0.88 | -0.8144 | -0.72 | -0.77 | -0.62 | -1.16 | -1.26 |
| Estimated EPS | -0.37 | -0.67 | -0.9372 | -1.07 | -0.93 | -0.85 | -0.8536 | -0.78 | -1.11 | -1.21 | -1.23 | -1.06 |
| Surprise | -0.35 | -0.2 | 0.6472 | 0.22 | -0.21 | -0.03 | 0.0392 | 0.06 | 0.34 | 0.59 | 0.07 | -0.2 |
| Surprise Percentage | -94.5946% | -29.8507% | 69.0568% | 20.5607% | -22.5806% | -3.5294% | 4.5923% | 7.6923% | 30.6306% | 48.7603% | 5.6911% | -18.8679% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCYC
2026-08-04 07:42:15
Bicycle Therapeutics PLC (BCYC) shows strong fundamentals and significant growth potential, despite recent weak market performance. TradingKey's analysis rates its valuation as fairly valued, with high institutional ownership. Analysts have given the stock a "Buy" rating, setting a high price target, though the stock is expected to trend down in the medium term.
2026-07-31 07:41:44
Bicycle Therapeutics plc reported its Q2 2026 financial results, showing a narrower loss per share of $0.72 despite a significant 78.5% decrease in revenue to $629,000. The company, focused on advancing its novel therapeutic platform, posted a net loss of $50.3 million as it continues its clinical-stage development. Analyst consensus remains cautiously optimistic with 7 buy ratings and 6 hold ratings.
2026-07-30 20:09:54
Bicycle Therapeutics (NASDAQ: BCYC) reported second-quarter earnings per share of $-0.72, missing analyst estimates by $0.15. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $4.35M. Following the announcement, Bicycle Therapeutics' stock price closed at $3.86, reflecting a significant decline over the past three and twelve months.
2026-07-30 18:39:34
Bicycle Therapeutics plc reported a narrower loss in Q2 2026 despite a significant drop in revenue. The clinical-stage pharmaceutical company posted a loss per share of $0.72, an improvement from the previous year, while revenue decreased by 78.5% to $629,000. Wall Street analysts maintain a cautiously optimistic outlook, with a consensus of 7 buy ratings and 6 hold ratings, reflecting confidence in the company's differentiated bicyclic peptide technology platform.
2026-07-30 16:39:33
Bicycle Therapeutics announced its second-quarter 2026 financial results and provided business updates, highlighting progress in its oncology therapeutic pipeline. The company reported $510.1 million in cash and cash equivalents, projecting a cash runway into 2030, following a refined focus on nuzefatide pevedotin and their next-generation Bicycle conjugate pipeline. Key clinical data presented at AACR and ASCO demonstrated promising anti-tumor activity and differentiated safety profiles for nuzefatide pevedotin and zelenectide pevedotin in various cancers, including pancreatic and urothelial cancer.
2026-07-30 13:11:13
Bicycle Therapeutics PLC (BCYC) reported a significant Q2 revenue decline, yet its GF Value™ suggests the stock is 71.0% undervalued. The company, a clinical-stage biotech, is focused on advancing its cancer pipeline despite being unprofitable and cash-flow negative, with a moderate GF Score™ indicating financial stability but weak profitability. Insider selling and mixed guru activity highlight the complex investment profile, suggesting potential value but also significant risk.
